Press Releases
All Pfizer published press releases by date and/or category of news
-
01.06.2020 Research BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma -
12.16.2019 Finance Research Pfizer Declares First-Quarter 2020 Dividend and Announces Upcoming Investor Day to Highlight Strength of Innovative R&D Pipeline -
12.07.2019 Research Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer -
12.07.2019 Research Sangamo and Pfizer Announce Updated Phase 1/2 Results Showing Sustained Increased Factor VIII Activity Through 44 Weeks Following SB-525 Gene Therapy Treatment -
11.15.2019 Research Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals -
11.12.2019 Research Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting -
11.08.2019 Research EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial -
10.21.2019 Research OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency -
10.12.2019 Research Pfizer Presents Positive Phase 3 Data at the 28th Congress of the European Academy of Dermatology and Venereology for Abrocitinib in Moderate to Severe Atopic Dermatitis -
10.07.2019 Partnerships Research Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-LRx -
09.29.2019 Research Pfizer Presents Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI® (Encorafenib), MEKTOVI® (Binimetinib) and Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer -
09.27.2019 Research Pfizer Announces Positive Top-Line Results from Second Pivotal Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib, in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis
Trust in Technology – A Snapshot
Pfizer surveyed adults in 10 countries across the Global North and South to better understand the general population's trust in incorporating technology into the management of their healthcare. The results showed that 6 in 10 trust technology in this setting but that means 4 in 10 are at risk of being left behind. Our findings underscored that patients won’t feel the full benefits of that technology if we don’t have trusted people – specifically health care providers – delivering it. We must partner with patients, healthcare providers, policy makers and others in the life sciences and tech industries to build trust in the technologies that are fueling the future of health.
Media Asset Library
A collection of assets for use by media.
Updates and Statements
Partnering News
The latest news from Pfizer and its strategic partners
-
05.20.2022 Corporate Partnerships NetVation DL Medicine Announces Research Collaboration with Pfizer Inc. -
04.27.2022 Corporate Partnerships Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.